Hyperkalemia complicating propranolol treatment of an infantile hemangioma

Pediatrics

Volumn 126, Issue 6, 2010, Pages

  Pavlaković, Helena ^a   Kietz, Silke ^a   Lauerer, Peter ^a   Zutt, Markus ^a   Lakomek, Max ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Adverse effects; Complication; Furosemide; Hyperkalemia; Infantile hemangioma; Propranolol; Salbutamol

Indexed keywords

C REACTIVE PROTEIN; CEFUROXIME; CREATININE; ELECTROLYTE; FUROSEMIDE; GLUCOSE; INFUSION FLUID; LACTATE DEHYDROGENASE; POTASSIUM; PROPRANOLOL; SALBUTAMOL; URIC ACID;

ANALGESIA; ARTICLE; BLOOD PRESSURE MONITORING; CASE REPORT; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DEBRIDEMENT; DISEASE SEVERITY; DIURESIS; DOPPLER ECHOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROLYTE BLOOD LEVEL; FEMALE; FEVER; FLUID RESUSCITATION; GLUCOSE BLOOD LEVEL; HEART RATE; HEMANGIOMA; HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPOTENSION; INFANT; INFANT DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SKIN NECROSIS; SKIN ULCER; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUPERINFECTION; URIC ACID BLOOD LEVEL; WOUND DRESSING;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALBUTEROL; FEMALE; FLUID THERAPY; FOLLOW-UP STUDIES; HEMANGIOMA; HUMANS; HYPERKALEMIA; INFANT; POTASSIUM; PROPRANOLOL; SKIN NEOPLASMS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; THORACIC WALL;

EID: 78649651541     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0077     Document Type: Article

References (37)

1. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341(3):173-181
2. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651
3. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope. 2009;119(10):2051- 2054
4. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3) Available at: www.pediatrics.org/cgi/content/full/124/3/e423
5. Cremer HJ. Hemangioma: classification and recommendations for therapy. [in German]. Pädiatrie Hautnah. 2009;10(2):133-146
6. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med. 2008;359(26):2846;author reply 2846-2847
7. Li YC, McCahon E, Rowe NA, Martin PA, Wilcsek GA, Martin FJ. Successful treatment of infantile haemangiomas of the orbit with propranolol. Clin Experiment Ophthalmol. 2010;38(6):554
8. Vanlander A, Decaluwe W, Vandelanotte M, Van Geet C, Cornette L. Propranolol as a novel treatment for congenital visceral haemangioma. Neonatology. 2010;98(3):229-231
9. Fay A, Nguyen J, Jakobiec FA, Meyer-Junghaenel L, Waner M. Propranolol for isolated orbital infantile hemangioma. Arch Ophthalmol. 2010;128(2):256-258
10. Naouri M, Schill T, Maruani A, Bross F, Lorette G, Rossler J. Successful treatment of ulcerated haemangioma with propranolol. J Eur Acad Dermatol Venereol. 2010;24(9):1109-1112
11. Taban M, Goldberg RA. Propranolol for orbital hemangioma. Ophthalmology. 2010;117(1):195.e1-195.e4
12. Truong MT, Chang KW, Berk DR, Heerema-McKenney A, Bruckner AL. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr. 2010;156(2):335-338
13. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26(5):610-614
14. Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162(2):466-468
15. Marsciani A, Pericoli R, Alaggio R, Brisigotti M, Vergine G. Massive response of severe infantile hepatic hemangioma to propanolol. Pediatr Blood Cancer. 2010;54(1):176
16. Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 2010;120(4):676-681
17. Payne WG, Salas RE, Ko F, et al. Enzymatic debriding agents are safe in wounds with high bacterial bioburdens and stimulate healing. Eplasty. 2008;8:e17
18. Tiras U, Erdeve O, Karabulut AA, Dallar Y, Eksioglu HM. Debridement via collagenase application in two neonates. Pediatr Dermatol. 2005;22(5):472-475 (Pubitemid 43961009)
19. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208-1213
20. Grantzow R, Schmittenbecher P, Cremer H, et al. Hemangiomas in infancy and childhood. Guideline of the German Society of Dermatology with the working group Pediatric Dermatology together with the German Society for Pediatric Surgery and the German Society for Pediatric Medicine. J Dtsch Dermatol Ges. 2008;6(4):324-329
21. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104(6):1616-1623
22. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140(8):963-969
23. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 2005;22(5):383-406
24. Tanel RE, Levin MD. Pharmacologic treatment of heart disease. In: Vetter VL, ed. Pediatric Cardiology: The Requisites in Pediatrics. Philadelphia, PA: Elsevier Mosby; 2006:263-265
25. Kannankeril PJ, Fish FA. Disorders of cardiac rhythm and conduction. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF, eds. Moss and Adams' Heart Disease in Infants, Children and Adolescents. 7th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008:296
26. Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med. 1980;302(8):431-434
27. Sørensen EV, Jensen HK, Faergeman O. Comparison of the effects of xamoterol, atenolol and propranolol on breathlessness, fatigue and plasma electrolytes during exercise in healthy volunteers. Eur J Clin Pharmacol. 1991;41(1):51-55
28. Lohmann FW, Loesment WA, Kaehler H. Beta-receptor blockade, physical activity, and metabolism. J Cardiovasc Pharmacol. 1990;16(suppl 5):S45-S52
29. Lundborg P. The effect of adrenergic blockade on potassium concentrations in different conditions. Acta Med Scand Suppl. 1983;672:121-126
30. British Medical Association Staff. British National Formulary 48. 48th ed. London, United Kingdom: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004
31. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163(2):269-274
32. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim. 2002;38(5):298-304 (Pubitemid 35204978)
33. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep. 1978;62(8):1117-1133 (Pubitemid 9015322)
34. Jona JZ. Progressive tumor necrosis and lethal hyperkalemia in a neonate with sacrococcygeal teratoma (SCT). J Perinatol. 1999;19(7):538-540
35. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11
36. Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol. 2005;147:61-68
37. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767-2778